Ceasing to be a substantial holder

Change in substantial holding

Change of Director’s Interest Notice

CEO and CSO Appointments

Share issue S708A cleansing notice

Application for listing $5m placement

Change of Director’s Interest Notice

S708A notice upon the issue of shares

S708 Notice for issue of shares

Appendix 3B application for listing

Final Director’s Interest Notice

Initial Director’s Interest Notice (two directors)

Operational Update March Quarter

Resignation of Secretary

Operational Update

Genentech extends research collaboration period

NHMRC Grant Awarded to Collaborators

AGM Presentation to Shareholders

Chair’s Address to Shareholders

Becoming a substantial holder

Appendix 4C – quarterly

Notice of Annual General Meeting/Proxy Form

Annual Report to shareholders

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Initial Director’s Interest Notice

Director Appointment

Cell-Penetrating Phylomers Improve Delivery of Drugs

Conference Presentation

Appendix 4C – Quarterly

Chair Appointment and Director Resignation

Final Director’s Interest Notice

Half Yearly Report and Accounts

Appendix 4C – Quarterly

Director Appointment

Initial Director’s Interest Notice

Combination Therapy Escalates Potency of Phylogica Peptides Against MYC-Driven Cancer

Shareholder Briefings

AGM Presentation

Change of Director’s Interest Notice

Proprietary Anti-Cancer Drug Candidates

Corporate Governance Statement

Animal Model Cancer Studies

Appendix 4C – Quarterly

Annual Report to Shareholders

Notice of Annual General Meeting/Proxy Form

Chairman Appointment

Annual General Meeting – 2015

Full Year Statutory Accounts

Preliminary Final Report

Change in Substantial Holding

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Confirmation of Release – PYC – Top 20 Shareholders

Change in Substantial Holding

Change of Director’s Interest Notice

Entitlement Issue Result and Shortfall

Entitlement Issue Supplementary Prospectus

Change of Director’s Interest Notice

Appendix 4C – Quarterly

Issue Closing Date Extended

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Entitlement Issue Closing Date Extended

Corrected Timetable – Non-Renounceable Issue

Australian Research Council Grant

Non-Renounceable Entitlement Issue

Letter to Option Holders

Phylogica Fully Underwritten Entitlement Issue to Raise $10m

Entitlement Issue Prospectus

Shareholder Update May 2015

Phylogica 2015 Investor Presentation

Phylogica Licenses Peptides to UK Company

Cancer Pilot Study Success

Joint Company Secretary Appointment

Half Year Statement

Europe Patent Phenotypic Screening

Shareholder Update February 2015

Appendix 4C – Quarterly Report

Phylogica Presentation at 2015 Biotech Showcase San Francisco

Change of Director’s Interest Notice

Appendix 3B – New Issue Announcement

Phylogica and Genentech Research & Licensing Agreement

2014 AGM Presentation

Annual General Meeting Results